Naftidrofuryl in Chronic Arterial Disease. Results of a Controlled Multicenter Study

In a double blind, randomized multicenter study naftidrofuryl, a vasoactive substance, was compared with placebo in the treatment of 104 patients with chronic arterial occlusive disease. After a run-in period of four weeks the pa tients received either naftidrofuryl (600mg daily) or placebo over 12...

Full description

Saved in:
Bibliographic Details
Published in:Angiology 1984-11, Vol.35 (11), p.701-708
Main Authors: Trübestein, G., Böhme, H., Heidrich, H., Heinrich, F., Hirche, H., Maass, U., Mörl, H., Rudofsky, G.
Format: Article
Language:English
Subjects:
Adult
Arterial Occlusive Diseases - drug therapy
Blood Flow Velocity
Blood Pressure
Chronic Disease
Clinical Trials as Topic
Double-Blind Method
Female
Furans - therapeutic use
Humans
Male
Middle Aged
Nafronyl - therapeutic use
Placebos
Statistics as Topic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a double blind, randomized multicenter study naftidrofuryl, a vasoactive substance, was compared with placebo in the treatment of 104 patients with chronic arterial occlusive disease. After a run-in period of four weeks the pa tients received either naftidrofuryl (600mg daily) or placebo over 12 weeks. The pain-free and the total walking distances improved significantly in both groups. However, the difference in the improvement of the pain-free walking distance was significant (p < 0.02) in favour of naftidrofuryl. There also was a difference in the improvement of the total walking distance in favour of naftidrofuryl which was not significant. The results indicate that naftidrofuryl has a beneficial effect on the symp toms and lengthens the painfree walking distance in patients with arterial occlu sive disease.
ISSN:0003-3197
1940-1574
DOI:10.1177/000331978403501103